Literature DB >> 19343154

Gastroesophageal cancer: understanding the disease process and advancing therapy.

John S Macdonald1.   

Abstract

Entities:  

Year:  2007        PMID： 19343154      PMCID： PMC2661562     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  19 in total

1.  Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

Authors:  Manish A Shah; Ramesh K Ramanathan; David H Ilson; Alissa Levnor; David D'Adamo; Eileen O'Reilly; Archie Tse; Robin Trocola; Lawrence Schwartz; Marinela Capanu; Gary K Schwartz; David P Kelsen
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

Authors:  Manish A Shah; David Ilson; David P Kelsen
Journal:  J Clin Oncol       Date:  2005-03-28       Impact factor: 44.544

3.  Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia.

Authors:  M D Gammon; J B Schoenberg; H Ahsan; H A Risch; T L Vaughan; W H Chow; H Rotterdam; A B West; R Dubrow; J L Stanford; S T Mayne; D C Farrow; S Niwa; W J Blot; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1997-09-03       Impact factor: 13.506

4.  Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors.

Authors:  Z F Zhang; R C Kurtz; M Sun; M Karpeh; G P Yu; N Gargon; J S Fein; S K Georgopoulos; S Harlap
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-10       Impact factor: 4.254

5.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

6.  Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia.

Authors:  W H Chow; W J Blot; T L Vaughan; H A Risch; M D Gammon; J L Stanford; R Dubrow; J B Schoenberg; S T Mayne; D C Farrow; H Ahsan; A B West; H Rotterdam; S Niwa; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1998-01-21       Impact factor: 13.506

7.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries.

Authors:  A M Bunt; J Hermans; V T Smit; C J van de Velde; G J Fleuren; J A Bruijn
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

9.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

10.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.